The Trump administration on Tuesday announced 15 drugs selected to participate in the latest round of the Medicare Drug Price Negotiation Program, including high-cost drugs Botox and Trulicity. This third cycle of negotiations is the first to include drugs payable under Medicare Part B, which are traditionally administered in clinical settings, in addition to…
Please follow and like us:
